Previous close | 211.03 |
Open | 225.50 |
Bid | 220.00 |
Ask | 226.05 |
Strike | 650.00 |
Expiry date | 2024-08-16 |
Day's range | 225.50 - 225.50 |
Contract range | N/A |
Volume | |
Open interest | 8 |
A US Food and Drug Administration (FDA) panel voted unanimously 11-0 to recommend the approval of Eli Lilly's (LLY) Alzheimer's drug, donanemab. Yahoo Finance's Anjalee Khemlani reports more on the story and the drug's ability to slow cognitive decline. Read more about donanemab here. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Considering how many Apple products there are out there in the world at this time, a high number of them will soon be accessing A.I. from an Apple device.
Eli Lilly stock jumped Monday after FDA advisors said the benefits of Alzheimer's treatment donanemab outweigh the risks for most patients.